Brokerages Set Establishment Labs Holdings Inc. (NASDAQ:ESTA) PT at $58.83

Shares of Establishment Labs Holdings Inc. (NASDAQ:ESTA) have been assigned a consensus recommendation of “Moderate Buy” from the five research firms that are presently covering the firm, Marketbeat reports. One investment analyst has rated the stock with a hold recommendation and four have assigned a buy recommendation to the company. The average twelve-month price target among brokers that have updated their coverage on the stock in the last year is $60.60.

Several equities analysts have recently weighed in on ESTA shares. JPMorgan Chase & Co. decreased their target price on Establishment Labs from $61.00 to $50.00 and set an “overweight” rating on the stock in a research report on Wednesday, August 7th. BTIG Research raised their target price on Establishment Labs from $62.00 to $65.00 and gave the company a “buy” rating in a research report on Monday, October 14th. Citigroup raised their target price on Establishment Labs from $45.00 to $50.00 and gave the company a “neutral” rating in a research report on Tuesday, October 1st. Finally, Stephens restated an “overweight” rating and issued a $68.00 target price on shares of Establishment Labs in a research report on Wednesday, August 7th.

Establishment Labs Stock Performance

Shares of ESTA stock opened at $46.25 on Friday. The company has a market capitalization of $1.29 billion, a P/E ratio of -17.93 and a beta of 1.20. The business’s 50 day moving average is $43.38 and its two-hundred day moving average is $45.86. Establishment Labs has a 12-month low of $19.83 and a 12-month high of $60.12. The company has a current ratio of 4.44, a quick ratio of 2.91 and a debt-to-equity ratio of 4.30.

Institutional Investors Weigh In On Establishment Labs

Several hedge funds and other institutional investors have recently made changes to their positions in ESTA. BNP Paribas Financial Markets increased its holdings in shares of Establishment Labs by 32,968.7% in the first quarter. BNP Paribas Financial Markets now owns 97,222 shares of the company’s stock valued at $4,949,000 after purchasing an additional 96,928 shares during the last quarter. Swiss National Bank increased its holdings in shares of Establishment Labs by 13.6% in the first quarter. Swiss National Bank now owns 37,500 shares of the company’s stock valued at $1,909,000 after purchasing an additional 4,500 shares during the last quarter. Concurrent Investment Advisors LLC acquired a new stake in shares of Establishment Labs in the first quarter valued at approximately $263,000. William Blair Investment Management LLC acquired a new stake in Establishment Labs during the first quarter worth $21,415,000. Finally, Vanguard Group Inc. increased its stake in Establishment Labs by 11.8% during the first quarter. Vanguard Group Inc. now owns 77,798 shares of the company’s stock worth $3,960,000 after acquiring an additional 8,210 shares during the last quarter. Institutional investors and hedge funds own 72.91% of the company’s stock.

Establishment Labs Company Profile

Establishment Labs Holdings Inc, a medical technology company, manufactures and markets medical devices for aesthetic and reconstructive plastic surgery. The company primarily offers silicone gel-filled breast implants under the Motiva Implants brand. It also provides Motiva Ergonomix and Motiva Ergonomix2 gravity sensitive round soft silicone-gel-filled breast implants; and Motiva Flora Tissue Expander, a breast tissue expander.